ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VRS Verisante Technology Inc

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Verisante Technology Inc TSXV:VRS TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Verisante Completes Private Placement

17/05/2013 8:49pm

Marketwired Canada


Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or
"Verisante"), announced today that it has closed its brokered private placement
of 2,357,500 units ("Units") at a price of $0.40 per Unit for gross proceeds of
$943,000 led by sole agent Raymond James Ltd. (the "Agent"). Each Unit consists
of one common share of the Company and one common share purchase warrant (a
"Warrant"). Each Warrant entitles the holder to acquire a common share at a
price of $0.60 for a period of 24 months from the date of issuance.


The Warrants shall have two call provisions whereby in the event the volume
weighted average trading price of Verisante's common shares on the TSX Venture
Exchange (the "Exchange") is equal to or greater than $0.90 for 10 consecutive
trading days, the Company will have the right to accelerate the expiry date of
50% of the total Warrants issued under the private placement to a date that is
30 days after Verisante issues a news release announcing that it has elected to
exercise this acceleration right. Under the second call provision, in the event
the volume weighted average trading price of Verisante's common shares on the
Exchange is equal to or greater than $1.15 for 10 consecutive trading days, the
Company will have the right to accelerate the expiry date of remaining 50% of
the total Warrants issued under the private placement to a date that is 30 days
after Verisante issues a news release announcing that it has elected to exercise
this acceleration right.


The private placement is subject to all necessary regulatory and stock exchange
approvals. Securities issued pursuant to the private placement are subject to a
hold period of four months plus one day from the date of distribution.


The net proceeds of the private placement will be used to fund the Company's
manufacturing of Aura(TM), to pursue additional regulatory approvals of Aura(TM)
in the United States and other regions, to support sales and marketing
initiatives, and for working capital requirements.


The Agent was paid a total of $60,400 as cash commission and was issued 151,000
agent's warrants in connection with this private placement.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an
Edison Award for Excellence in Innovation in 2013. Verisante Core(TM) was named
one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.


Forward Looking Statements

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com


Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

1 Year Verisante Technology Chart

1 Year Verisante Technology Chart

1 Month Verisante Technology Chart

1 Month Verisante Technology Chart

Your Recent History

Delayed Upgrade Clock